Novel gene targeting therapies, protein disruptors and why ANP's recent trial success have investors buzzing - a podcast by Stockhead
from 2020-02-05T15:01
::
::
Tim speaks with Antisense (ASX:ANP) managing director and CEO, Mark Diamond
Further episodes of The Health Kick Podcast with Tim Boreham
Further podcasts by Stockhead
Website of Stockhead